Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within minutes and DPP-4 inhibitors are therefore used for treatment of diabetic hyperglycemia. A few animal studies have implicated the enzyme neutral endopeptidase 24.11 (24.11) in the degradation of GLP-1 but if this is the case in humans with type 2 diabetes is unknown. We therefore administered a NEP inhibitor, 194mg sacubitril, a DPP-4 inhibitor (sitagliptin 100mg the night before and 100mg 2 hours before), both, or placebo, to patients with type 2 diabetes during a standardized meal and measured plasma concentrations of GLP-1
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Single dose administration of entresto
Single dose administration of sitagliptin
single doses administration of valsartan
placebo day
Hvidovre Hospital
Hvidovre, RegionH, Denmark
Blood Glucose
Plasma Concentrations of glucose
Time frame: 3 hours after treatment ( during the subsequent standardized meal)
Plasma Concentrations of GLP-1
Time frame: 3 hours after treatment ( during the subsequent standardized meal)
Plasma Concentrations of GIP
Time frame: 3 hours after treatment ( during the subsequent standardized meal)
Plasma Concentrations of Glucagon
Time frame: 3 hours after treatment ( during the subsequent standardized meal)
Plasma Concentrations of Insulin
Time frame: 3 hours after treatment ( during the subsequent standardized meal)
Plasma Concentrations of C-Peptide
Time frame: 3 hours after treatment ( during the subsequent standardized meal)
Plasma Concentrations of Amino Acids
Time frame: 3 hours after treatment ( during the subsequent standardized meal)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.